| Quarterly Financials | Mar 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 216 | 278 | 260 | 293 | 331 | 402 | 300 | 296 | 300 | 303 | 334 | 328 | 342 | 282 | 314 | 293 | 326 | 384 | 318 | 338 | 319 | 407 | 432 | 421 | 545 | 438 | 450 | 516 | 547 | 596 |
| Expenses | 192 | 260 | 276 | 318 | 325 | 350 | 294 | 295 | 292 | 277 | 305 | 288 | 296 | 255 | 300 | 284 | 313 | 302 | 311 | 352 | 345 | 419 | 395 | 407 | 435 | 532 | 403 | 452 | 448 | 504 |
| EBITDA | 24 | 18 | -16 | -25 | 5 | 52 | 6 | 1 | 8 | 26 | 29 | 40 | 46 | 27 | 14 | 9 | 13 | 83 | 7 | -14 | -26 | -12 | 37 | 14 | 110 | -94 | 47 | 64 | 99 | 93 |
| Operating Profit % | -3 % | -10 % | -14 % | -22 % | -7 % | 7 % | -7 % | -10 % | -6 % | 5 % | 4 % | 9 % | 9 % | 7 % | -1 % | 2 % | -0 % | 19 % | -0 % | -7 % | -14 % | -4 % | 7 % | 2 % | 7 % | -23 % | 10 % | 11 % | 16 % | 14 % |
| Depreciation | 11 | 14 | 14 | 16 | 18 | 19 | 18 | 21 | 20 | 23 | 21 | 21 | 21 | 22 | 22 | 22 | 23 | 23 | 25 | 28 | 31 | 30 | 29 | 30 | 32 | 27 | 28 | 32 | 31 | 30 |
| Interest | 0 | 3 | 1 | 1 | 1 | 4 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 3 | 5 | 4 | 6 | 6 | 7 | 6 | 5 | 4 | 5 | 7 | 6 |
| Profit Before Tax | 13 | 2 | -31 | -43 | -14 | 29 | -14 | -22 | -13 | 0 | 7 | 18 | 24 | 3 | -9 | -16 | -11 | 58 | -21 | -47 | -61 | -47 | 2 | -22 | 73 | -126 | 15 | 27 | 62 | 58 |
| Tax | -16 | 4 | -10 | -2 | -14 | -9 | -8 | 1 | 1 | 18 | 5 | 9 | -0 | 3 | 2 | -3 | 3 | -14 | 3 | 23 | 3 | -3 | 3 | 3 | 0 | 3 | 6 | 3 | 4 | 5 |
| Net Profit | 29 | -2 | -21 | -41 | -0 | 38 | -6 | -22 | -15 | -17 | 2 | 9 | 24 | -0 | -12 | -13 | -14 | 72 | -23 | -71 | -64 | -44 | -1 | -25 | 73 | -129 | 9 | 25 | 58 | 53 |
| EPS in ₹ | 3.19 | 0.00 | -2.91 | -5.83 | -0.04 | 4.51 | -0.88 | -3.15 | -2.07 | -2.44 | 0.35 | 1.24 | 3.35 | -0.06 | -1.63 | -1.82 | -2.01 | 10.15 | -3.32 | -10.04 | -9.08 | -6.28 | -0.09 | -3.48 | 10.39 | -18.37 | 1.31 | 3.50 | 8.22 | 7.52 |
Unichem Laboratories
590.85
-6.55
(-1.10%)
Market Cap
4,206.00 Cr
EPS
19.53
PE Ratio
30.43
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
937.95
52 Week Low
511.55
PB Ratio
1.70
Debt to Equity
0.14
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,672.00 | #1 3,98,889.40 | 35.03 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 47.52 | |
6,835.00 | 1,81,700.00 | 82.80 | 9,360.00 | 0.89 | 2,117 | 23.05 | 58.12 | |
1,485.00 | 1,19,363.10 | 23.31 | 28,409.50 | 7.12 | 5,291 | 30.28 | 45.00 | |
3,314.20 | 1,13,020.50 | 58.54 | 11,539.40 | 11.59 | 1,911 | 10.91 | 53.58 | |
1,254.70 | 1,05,372.90 | #1 18.86 | 33,741.20 | 12.36 | 5,725 | 21.14 | 39.63 | |
2,578.30 | 1,04,998.20 | 53.56 | 12,207.40 | 19.57 | 1,925 | -10.91 | 70.20 | |
979.60 | 97,901.50 | 21.11 | 22,573.80 | 13.82 | 3,977 | -0.19 | 55.12 | |
1,894.70 | 86,534.70 | 26.34 | 22,192.10 | #1 19.94 | 3,024 | #1 112.49 | 36.85 | |
34,420.00 | 73,427.00 | 51.70 | 6,409.15 | 10.80 | 1,417 | 27.83 | 60.71 | |
1,124.80 | 65,624.80 | 18.90 | 31,378.10 | 17.55 | 3,366 | -0.50 | 44.29 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
25.70 %
Net Income Growth
-65.13 %
Cash Flow Change
-150.14 %
ROE
-64.10 %
ROCE
-74.64 %
EBITDA Margin (Avg.)
-1,588.24 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,169 | 1,284 | 1,527 | 3,194 | 3,150 | 3,145 | 3,126 | 3,319 | 3,193 | 3,275 | 3,569 |
| Fixed Assets | 416 | 403 | 491 | 578 | 810 | 870 | 884 | 990 | 1,257 | 1,252 | 1,300 |
| Current Assets | 564 | 600 | 749 | 2,337 | 2,038 | 1,687 | 1,377 | 1,648 | 1,589 | 1,743 | 2,030 |
| Capital Work in Progress | 123 | 237 | 250 | 238 | 92 | 331 | 568 | 494 | 148 | 123 | 31 |
| Investments | 35 | 14 | 14 | 901 | 926 | 550 | 392 | 264 | 2 | 1 | 0 |
| Other Assets | 595 | 630 | 772 | 1,476 | 1,321 | 1,395 | 1,282 | 1,571 | 1,787 | 1,899 | 2,239 |
| Total Liabilities | 1,169 | 1,284 | 1,527 | 3,194 | 3,150 | 3,145 | 3,126 | 3,319 | 3,193 | 3,275 | 3,569 |
| Current Liabilities | 212 | 243 | 393 | 464 | 503 | 567 | 506 | 552 | 640 | 738 | 992 |
| Non Current Liabilities | 89 | 86 | 70 | 50 | 27 | 47 | 63 | 148 | 118 | 99 | 127 |
| Total Equity | 868 | 954 | 1,064 | 2,680 | 2,620 | 2,531 | 2,557 | 2,618 | 2,435 | 2,438 | 2,451 |
| Reserve & Surplus | 849 | 936 | 1,045 | 2,666 | 2,606 | 2,517 | 2,543 | 2,604 | 2,421 | 2,424 | 2,437 |
| Share Capital | 18 | 18 | 18 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -25 | -7 | -1 | 655 | -616 | -78 | -154 | 32 | 75 | -29 | -65 |
| Investing Activities | -52 | -85 | -128 | 1,648 | -286 | -36 | -66 | 100 | 241 | 63 | -242 |
| Operating Activities | 78 | 112 | 68 | -112 | -328 | 20 | 33 | -260 | -85 | 14 | -7 |
| Financing Activities | -51 | -33 | 59 | -881 | -2 | -62 | -121 | 191 | -81 | -106 | 184 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 50.93 % | 50.93 % | 50.93 % | 50.93 % | 50.93 % | 50.93 % | 50.93 % | 50.93 % | 50.93 % | 50.93 % | 70.21 % | 70.22 % | 70.22 % | 70.22 % | 70.22 % | 70.22 % | 70.22 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.83 % | 0.00 % | 0.90 % | 0.89 % | 0.94 % | 1.06 % | 0.98 % |
| DIIs | 8.49 % | 8.49 % | 8.49 % | 8.49 % | 8.49 % | 8.38 % | 7.55 % | 8.20 % | 8.16 % | 7.39 % | 10.32 % | 9.29 % | 11.27 % | 11.58 % | 11.67 % | 11.63 % | 11.32 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 30.48 % | 30.39 % | 30.50 % | 30.27 % | 29.81 % | 29.95 % | 30.17 % | 30.99 % | 30.91 % | 26.86 % | 15.80 % | 15.63 % | 15.12 % | 14.80 % | 14.58 % | 14.47 % | 14.80 % |
| Others | 10.09 % | 10.19 % | 10.08 % | 10.31 % | 10.77 % | 10.73 % | 11.34 % | 9.87 % | 9.99 % | 14.81 % | 2.84 % | 4.85 % | 2.49 % | 2.50 % | 2.60 % | 2.62 % | 2.67 % |
| No of Share Holders | 0 | 33,734 | 34,258 | 33,892 | 35,313 | 33,557 | 32,666 | 29,573 | 29,418 | 26,642 | 21,584 | 20,877 | 21,171 | 20,621 | 20,374 | 21,472 | 21,621 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 5 | 4 | 4 | 4 | 4 | 4 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.05 | 2.57 | 2.57 | 1.29 | 1.54 | 1.39 | 0.81 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 04 Aug 2025 |  Annual General Meeting | NA | 04 Aug 2025 | 570.15 | 590.85 |
| 22 May 2025 |  Quarterly Result Announcement | NA | 22 May 2025 | 567.75 | 609.20 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 676.25 | 723.80 |
| 13 Nov 2024 | Quarterly Result Announcement | NA | 13 Nov 2024 | 802.45 | 877.05 |
| 08 Aug 2024 | Annual General Meeting | NA | 08 Aug 2024 | 537.10 | 582.45 |
| 03 Aug 2022 |  Dividend | ₹ 4.00 /share | 01 Aug 2022 | 232.65 | 295.00 |
| 26 Jul 2021 | Dividend | ₹ 4.00 /share | 22 Jul 2021 | 360.90 | 334.65 |
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
3 days ago
3 days agoAnnouncement Under Regulation 30 (LODR) Regulation 2015 - Update6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication6 days ago
6 days agoNotice Of 62Nd Annual General Meeting8 days ago
8 days agoBusiness Responsibility and Sustainability Reporting (BRSR)8 days ago
8 days agoReg. 34 (1) Annual Report.8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationJun 28, 2025
Jun 28, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025USFDA Audit Of Our Roha API FacilityJun 21, 2025
Jun 21, 2025Annual General Meeting On 4Th August 2025Jun 20, 2025
Jun 20, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
May 31, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2025
May 23, 2025Results For Quarter And Year Ended 2025May 22, 2025
May 22, 2025Board Meeting Outcome for OutcomeMay 22, 2025
May 22, 2025USFDA Inspection Report For Pithampur API PlantMay 14, 2025
May 14, 2025Board Meeting Intimation for Consider And Approve Financial Results For Quarter And Year Ended March 31 2025May 08, 2025
May 08, 2025Intimation Of Change In Contact Details Of Registrar And Share Transfer Agent (RTA)Apr 18, 2025
Apr 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Apr 08, 2025Board Meeting Outcome for Outcome Of Board MeetingMar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Announcement Under Regulation 30Mar 20, 2025
Mar 20, 2025USFDA Approval For CompanyS Pithampur API FacilityMar 01, 2025
Mar 01, 2025Board Meeting Outcome for Outcome Of Board MeetingMar 01, 2025
Mar 01, 2025Announcement under Regulation 30 (LODR)-Credit RatingFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Feb 07, 2025Integrated Filing (Financial)Feb 06, 2025
Feb 06, 2025Financial ResultsFeb 06, 2025
Feb 06, 2025Included Mr. Utkarsh Patil Chief Manufacturing Officer - Formulations As A Senior Management Personnel Under SEBI LODR Regulations With Effect From 6Th February 2025Feb 06, 2025
Feb 06, 2025Board Meeting Outcome for Unaudited Financial Results (Consolidated & Standalone) For The Quarter And Nine-Months Ended 31St December 2024Feb 06, 2025
Feb 06, 2025Announcement Under Regulation 30(LODR) - GST (Goods
&Services Tax)Jan 27, 2025
Jan 27, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.Jan 24, 2025
Jan 24, 2025Board Meeting Intimation for Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31 2024.Jan 14, 2025
Jan 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Jan 07, 2025Intimation By Registrar & Transfer Agent (RTA)Jan 03, 2025
Jan 03, 2025Resignation Of Senior Managerial Personnel.Dec 17, 2024
Dec 17, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2024
Nov 14, 2024Amendment In Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive InformationNov 13, 2024
Nov 13, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 13, 2024
Nov 13, 2024Board Meeting Outcome for Unaudited Financial Statements (Consolidated & Standalone) For The Second Quarter And Half Year Ended 30Th September 2024Nov 13, 2024
Nov 13, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 10, 2024
Nov 10, 2024Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended September 30, 2024.Oct 25, 2024
Oct 25, 2024Reply Letter On A Significant Increase In The Volume.Oct 23, 2024
Oct 23, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 11, 2024
Oct 11, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 04, 2024
Oct 04, 2024Board Meeting Outcome for Outcome Of Board MeetingSep 30, 2024
Sep 30, 2024Closure of Trading WindowSep 23, 2024
Sep 23, 2024Board Meeting Intimation for Integration And Consolidation Of The Generics FormulationsBusiness In The US Market.Sep 23, 2024
Sep 23, 2024Intimation Under Regulation 30 Of SEBI LODRSep 10, 2024
Sep 10, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2024
Sep 03, 2024Technical Indicators
RSI(14)
Neutral 47.15
ATR(14)
Less Volatile 18.66
STOCH(9,6)
Neutral 46.82
STOCH RSI(14)
Neutral 61.84
MACD(12,26)
Bullish 0.90
ADX(14)
Weak Trend 9.93
UO(9)
Bearish 36.61
ROC(12)
Downtrend And Accelerating -1.56
WillR(14)
Neutral -75.18
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth | 0.15% | -92564 | -0.11% | -0.12% | |
 Quant Value Fund Direct - Growth | 0.48% | 86600 | 0.27% | 0.26% | |
 HDFC Small Cap Fund Direct- Growth | 0.90% | -14489 | -0.06% | -0.17% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.09% | 5 | -0.01% | -0.01% | |
 DSP Healthcare Fund Direct - Growth | 1.64% | 0 | -0.08% | -0.12% | |
 Franklin India Opportunities Direct Fund-Growth | 0.00% | 0 | 0.00% | -0.15% | |
| HDFC Pharma And Healthcare Fund Direct - Growth | 0.00% | 0 | 0.00% | 0.00% |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
